(Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals’ drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder.
The drug, Dawnzera, is approved to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults and pediatric patients over 12 years old.
The condition causes frequent attacks of severe swelling in various parts of the body, including the hands, feet, genitals and face.
Dawnzera will be available in the U.S. in the coming days, the company said.
HAE is estimated to affect about 7,000 patients in the U.S., according to Ionis.
(Reporting by Bageshri Banerjee and Sneha S K in Bengaluru; Editing by Tasim Zahid and Leroy Leo)
Comments